drugset
Drugs / NAP
last change Apr 2009 re-read 3 minutes ago

NAP

Peptide

Developed for
schizophrenia
Investigated by
Beth Israel Deaconess Medical Center · Columbia University · Duke University · Massachusetts General Hospital · Nathan Kline Institute for Psychiatric Research · University of California, Los Angeles
+2 more · University of Maryland · Washington University School of Medicine

Trials 1

today NCT00505765 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00505765 Jul 2007 → Apr 2009 schizophrenia University of California, Los Angeles Completed Missed primary

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NAP “AL-108 is an intranasal drug product containing NAP, an 8 amino-acid peptide (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; NAPVSIPQ, MW=824.9) fragment of the much larger (approx. 124KD)...” NCT00505765 ↗
Modality Peptide “NAP, an 8 amino-acid peptide” NCT00505765 ↗